Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,310 Million (Large Cap)
15.00
NA
3.81%
-0.56
24.43%
3.68
Revenue and Profits:
Net Sales:
924 Million
(Quarterly Results - Jun 2025)
Net Profit:
301 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.0%
0%
17.0%
6 Months
10.52%
0%
10.52%
1 Year
15.93%
0%
15.93%
2 Years
1.88%
0%
1.88%
3 Years
43.87%
0%
43.87%
4 Years
-16.6%
0%
-16.6%
5 Years
15.27%
0%
15.27%
Tibet Rhodiola Pharmaceutical Holding Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.51%
EBIT Growth (5y)
20.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.64
Sales to Capital Employed (avg)
0.68
Tax Ratio
8.47%
Dividend Payout Ratio
60.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
38.04%
ROE (avg)
17.58%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.68
EV to EBIT
14.29
EV to EBITDA
13.47
EV to Capital Employed
7.10
EV to Sales
4.62
PEG Ratio
NA
Dividend Yield
3.81%
ROCE (Latest)
49.70%
ROE (Latest)
24.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
923.90
705.00
31.05%
Operating Profit (PBDIT) excl Other Income
333.70
248.90
34.07%
Interest
2.00
0.00
Exceptional Items
0.60
-1.40
142.86%
Consolidate Net Profit
300.50
270.20
11.21%
Operating Profit Margin (Excl OI)
341.20%
353.00%
-1.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 31.05% vs 12.87% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 11.21% vs 3.17% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,769.60
3,096.20
-10.55%
Operating Profit (PBDIT) excl Other Income
967.90
1,101.10
-12.10%
Interest
9.60
12.00
-20.00%
Exceptional Items
-18.80
-399.00
95.29%
Consolidate Net Profit
1,057.10
810.20
30.47%
Operating Profit Margin (Excl OI)
322.70%
335.70%
-1.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.55% vs 22.76% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 30.47% vs 115.88% in Dec 2023
About Tibet Rhodiola Pharmaceutical Holding Co. 
Tibet Rhodiola Pharmaceutical Holding Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






